Pierre Fabre Medicament

Thierry Champion

Liliane Goetsch

Charlotte Beau-Larvor

Matthieu Broussas

Alain Robert

Michel Perez

Jean-François Haeuw

Marie Lamothe

Ian Rilatt

Alexandra Jouhanneaud

The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.

IGF-1R antibody-drug-conjugate and its use for the treatment of cancer

The present invention relates to an antibody, in particular a monoclonal antibody, capable of binding to IGF-1R, as well as the amino and nucleic acid sequences coding for said antibody. From one aspect, the invention relates to an antibody, or an antigen binding fragment thereof, capable of binding to IGF-1R and, by inducing internalization of IGF-1R, being internalized into the cell. The invention also comprises the use of said antibody as an addressing product or vehicle in conjugation with other anti-cancer compounds such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.

IGF-1R antibody and its use as addressing vehicle for the treatment of cancer

The present invention relates to a method for the treatment of IGF-IR expressing cancers as well as to a compositions and a kit for said traitment. From one aspect, the invention relates to the combined use of a first antibody for the determination of the IGF-IR status of a cancer and a second antibody used as an ADC for the treatment of said cancer.

Composition for the treatment of IGF-1R expressing cancer

Growing community of inventors

Saint Julien en Genevois, France

Thierry Champion